Danaher Co. (NYSE:DHR) Shares Bought by Modern Wealth Management LLC

Modern Wealth Management LLC lifted its holdings in shares of Danaher Co. (NYSE:DHR) by 30.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,087 shares of the conglomerate’s stock after buying an additional 254 shares during the period. Modern Wealth Management LLC’s holdings in Danaher were worth $250,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Kentucky Retirement Systems Insurance Trust Fund raised its stake in shares of Danaher by 11.6% during the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate’s stock valued at $4,874,000 after purchasing an additional 2,202 shares in the last quarter. ORG Partners LLC raised its position in shares of Danaher by 1,212.8% during the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after buying an additional 2,559 shares in the last quarter. Generate Investment Management Ltd acquired a new stake in shares of Danaher in the 4th quarter worth approximately $8,044,000. Stifel Financial Corp increased its stake in shares of Danaher by 1.3% during the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after acquiring an additional 11,216 shares during the period. Finally, Compass Capital Management Inc. lifted its position in Danaher by 4.8% in the fourth quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate’s stock worth $54,615,000 after purchasing an additional 10,994 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of DHR opened at $205.69 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The firm has a market cap of $147.01 billion, a PE ratio of 38.96, a PEG ratio of 2.66 and a beta of 0.82. The firm’s 50 day moving average price is $214.57 and its 200 day moving average price is $236.90. Danaher Co. has a twelve month low of $196.80 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the firm posted $2.09 earnings per share. As a group, research analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. Danaher’s dividend payout ratio is currently 24.24%.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Barclays cut their price objective on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research note on Friday, December 13th. Jefferies Financial Group cut their target price on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Robert W. Baird decreased their price target on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Finally, Citigroup cut their price objective on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.24.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.